The Fly

BioMarin price target raised to $120 from $100 at Jefferies

Jefferies analyst Akash Tewari raised the firm’s price target on BioMarin to $120 from $100 and keeps a Buy rating on the shares after having surveyed 25 EU hemophilia A doctors and seeing signals of demand "out of the gate." 80 patients in Germany could get on Roctavian once it is available, which would imply sales above what is modeled by the Street for Q4 of 2022 to Q2 of 2023, said Tewari based on the survey, adding that safety was noted as one of the reasons that some patients may decide to wait first.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on BMRN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More